|
Application for quotation of securities - PTX
|
14 June 2023 at 4:00pm
|
|
Two PTX abstracts accepted at prestigious ISCT conference
|
16 May 2023 at 9:20am
|
|
Initial Director's Interest Notice
|
15 May 2023 at 2:59pm
|
|
Notification regarding unquoted securities - PTX
|
15 May 2023 at 2:59pm
|
|
Experienced Pharma Executive Joins Prescient Board
|
15 May 2023 at 2:20pm
|
|
Notification of cessation of securities - PTX
|
5 May 2023 at 11:05am
|
|
Change of Director's Interest Notices x3
|
2 May 2023 at 4:20pm
|
|
Application for quotation of securities - PTX
|
1 May 2023 at 1:10pm
|
|
Section 708A Cleansing Notice
|
1 May 2023 at 1:10pm
|
|
March 2023 Quarterly Update and Appendix 4C
|
28 April 2023 at 9:40am
|
|
Change of Director's Interest Notices x2
|
4 April 2023 at 5:20pm
|
|
Application for quotation of securities - PTX
|
4 April 2023 at 4:55pm
|
|
Exercise and Expiry of Listed Options
|
4 April 2023 at 4:55pm
|
|
Continued promising results in PTX-100 TCL trial
|
16 March 2023 at 10:15am
|
|
FDA grants broader orphan drug status to PTX100 for TCLs
|
9 March 2023 at 9:35am
|
|
Revised Securities Trading Policy
|
27 February 2023 at 3:45pm
|
|
Appendix 4D and Half Year Financial Report
|
24 February 2023 at 2:00pm
|
|
Notification of Expiry of Listed Options
|
22 February 2023 at 6:45pm
|
|
Application for quotation of securities - PTX
|
9 February 2023 at 3:00pm
|
|
December 2022 Quarterly Update and Appendix 4C
|
25 January 2023 at 2:10pm
|
|
Application for quotation of securities - PTX
|
25 January 2023 at 9:15am
|
|
Application for quotation of securities - PTX
|
5 January 2023 at 3:45pm
|
|
Change of Director's Interest Notice
|
14 December 2022 at 4:30pm
|
|
Notification of cessation of securities - PTX
|
14 December 2022 at 4:25pm
|
|
Section 708A Cleansing Notice
|
14 December 2022 at 4:25pm
|
|
Application for quotation of securities - PTX
|
14 December 2022 at 4:25pm
|
|
Application for quotation of securities - PTX
|
9 December 2022 at 8:50am
|
|
Results of Annual General Meeting
|
29 November 2022 at 3:00pm
|
|
AGM Presentation
|
29 November 2022 at 11:20am
|
|
Chair's Address to the 2022 Annual General Meeting
|
29 November 2022 at 11:15am
|
|
Application for quotation of securities - PTX
|
15 November 2022 at 2:50pm
|
|
PTX Investor presentation and additional patient response
|
2 November 2022 at 9:05am
|
|
September 2022 Quarterly Update and Appendix 4C
|
31 October 2022 at 9:30am
|
|
Notice of Annual General Meeting/Proxy Form
|
27 October 2022 at 3:50pm
|
|
PTX-100 Trial Update
|
25 October 2022 at 9:50am
|
|
Application for quotation of securities - PTX
|
17 October 2022 at 3:20pm
|
|
Section 708A Cleansing Notice
|
17 October 2022 at 3:20pm
|
|
Application for quotation of securities - PTX
|
13 October 2022 at 11:35am
|
|
Change of Director's Interest Notices x2
|
12 October 2022 at 1:59pm
|
|
Application for quotation of securities - PTX
|
11 October 2022 at 12:10pm
|
|
Proposed issue of securities - PTX
|
11 October 2022 at 10:20am
|
|
Placement Results
|
11 October 2022 at 10:20am
|
|
SPP Results and Placement
|
7 October 2022 at 10:10am
|
|
Trading Halt
|
7 October 2022 at 10:05am
|
|
Extension of Share Purchase Plan
|
28 September 2022 at 10:10am
|
|
CellPryme-A Investor Presentation
|
27 September 2022 at 10:15am
|
|
PTX unveils CellPryme-A to boost CAR-T performance
|
23 September 2022 at 9:15am
|
|
Prescient unveiling CellPryme-A at CAR-TCR summit in Boston
|
14 September 2022 at 10:05am
|
|
Application for quotation of securities - PTX
|
9 September 2022 at 12:05pm
|
|
PTX strategic collaboration with MD Anderson Cancer Center
|
7 September 2022 at 9:10am
|
Prescient Therapeutics